BRAF and thyroid gland carcinoma: Multi-kinase inhibitors targeting the MAPK pathway, such as Vermurafenib (BRAF) and Selumetinib (MEK) are under study for advanced thyroid cancers, though none of them have yet been approved by the FDA.